Business
Eupraxia Pharmaceuticals Enters Collaborative Partnership with NBCD for Lead Osteoarthritis (OA) Product Candidate
Eupraxia Pharmaceuticals Enters Collaborative Partnership with NBCD for Lead Osteoarthrit...
About this update from Eupraxia Pharmaceuticals, Inc.
[{"type":"text","content":"\n \n \n \n Eupraxia Pharmaceuticals Enters Collaborative Partnership with NBCD for Lead Osteoarthritis (OA) Product Candidate\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n \n NBCD (Nordic Bioscience Clinical Development) to make strategic investment on the same terms of Eupraxia's recently completed IPO\n \n \n \n \n \n \n VICTORIA, BC\n \n ,\n \n April 14, 2021\n \n /CNW/ - Eupraxia Pharmaceuticals Inc. (\"Eupraxia\" or the \"Company\") (TSX: EPRX), a clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced that it has entered into an agreement (the \"CTO Agreement\") with NBCD A/S (\"NBCD\"), a contract research organisation dedicated to clinical drug development and research in OA, to conduct Eupraxia's EP-104IAR Phase 2 clinical trial that will initiate later this year.\n \n \n Pursuant to the CTO Agreement, NBCD has also agreed to make a\n \n US$500,000\n \n investment in Eupraxia (the \"Equity Investment\") on the same terms as Eupraxia's recently completed initial public offering, as further detailed below. NBCD's subscription for the Equity Investment will be satisfied by setting off\n \n US$500,000\n \n of service fees otherwise payable by Eupraxia to NBCD under the CTO Agreement and allows Eupraxia to expand enrollment in its EP-104IAR Phase 2 clinical trial.\n \n \n Eupraxia's Phase 2 study is a placebo-controlled, double-blind, randomized trial evaluating the efficacy and safety of EP-104IAR in 300 patients with knee OA.  NBCD will initiate the trial at three clinical research centres in Denmark with a proven track record in osteoarthritis clinical trials, with results expected in the fourth quarter of 2022. NBCD also maintains a global operational footprint, allowing Eupraxia to expand current and future trials into\n \n the United States\n \n and other geographies.\n \n \n \"NBCD is a strong clinical trial partner with a global reputation in the OA space,\" said\n \n James A. Helliwell\n \n , MD, Chief Executive Officer of Eupraxia. \"NBCD's i...